ArticleThe open virology journal2007
Targeted strategies for henipavirus therapeutics.
Article in The open virology journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- EPHA2 Receptor as a Possible Therapeutic Target in Viral Infections.Current medicinal chemistry · 2024Review
- Mouse Models of Henipavirus Infection.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Henipavirus infections: lessons from animal models.Pathogens (Basel, Switzerland) · 2013Review
- A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.Science translational medicine · 2012Article
- Animal challenge models of henipavirus infection and pathogenesis.Current topics in microbiology and immunology · 2012Review
- A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge.Science translational medicine · 2011Article
- Hendra and nipah infection: pathology, models and potential therapies.Infectious disorders drug targets · 2011Review
- Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.PloS one · 2010Article
- Chloroquine administration does not prevent Nipah virus infection and disease in ferrets.Journal of virology · 2009Article
- A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats.Vaccine · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hendra and Nipah viruses are related emergent paramyxoviruses that infect and cause disease in animals and humans. Disease manifests as a generalized vasculitis affecting multiple organs, but is the most severe in the respiratory and central nervous systems. The high case fatality and person-to-person transmission associated with the most recent NiV outbreaks, and the recent re-emergence of HeV, emphasize the importance and necessity of effective therapeutics for these novel agents. In recent years henipavirus research has revealed a more complete understanding of pathogenesis and, as a consequence, viable approaches towards vaccines and therapeutics have emerged. All strategies target early steps in viral replication including receptor binding and membrane fusion. Animal models have been developed, some of which may prove more valuable than others for evaluating the efficacy of therapeutic agents and regimes. Assessments of protective host immunity and drug pharmacokinetics will be crucial to the further advancement of therapeutic compounds.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.